CTRI/2015/03/005644
Recruiting
Phase 2
CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OFCAPSULE DIAGUARDâ?? A POLYHERBAL ANTI-DIABETIC DRUG IN PATIENTS WITH TYPE II DIABETES MELLITUS (T2DM)A DOUBLE BLIND PLACEBO CONTROLLED TRIAL - DIGD
Charak Pharma Pvt Ltd CPPL Mumbai0 sites60 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- ADULT PATIENTS WITH NEWLY DIAGNOSED DIABETES MELLITUS
- Sponsor
- Charak Pharma Pvt Ltd CPPL Mumbai
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion Criteria
- •The participant may enter the trial if ALL of the following apply:
- •Participant is willing and able to give informed consent for participation in the trial
- •Male or female, aged 21 to 65 years
- •Diagnosed with Type 2 DM, whose fasting plasma glucose (FPG) is greater than 150 mg% and/or Post lunch (2 hrs) plasma glucose (PPPG) is greater than 200 mg%
- •HbA1c in range of 7% to 10%
- •Participant has clinically acceptable laboratory results
- •In the investigatorâ??s opinion is able and willing to comply with all trial requirements
Exclusion Criteria
- •Exclusion Criteria
- •The participant may not enter the trial if ANY of the following apply:
- •Female participant who is pregnant, lactating or planning pregnancy Type I DM patients
- •Type II DM patients who require insulin or OHAs for management of diabetic complications
- •FPG equal or less than 150 mg % and PPPG equal or less than 200 mg %
- •HbA1c greater than 10
- •Significant cardiac, renal or hepatic impairment
- •Scheduled elective surgery or other procedures requiring general anaesthesia during the trial
- •Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participantâ??s ability to participate in the trial
- •Participants who have participated in another research trial involving an investigational product in the past 12 weeks
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
To Find the Effect of CORDYCEPS POWDER as a Nutritional supplementHealth Condition 1: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2022/03/040721DXN Manufacturing India Pvt Ltd24
Completed
Phase 2
To Find the Effect of LION�S MANE POWDER as Nutritional Supplement.Health Condition 1: E648- Sequelae of other nutritional deficienciesCTRI/2022/03/040724DXN Manufacturing India Pvt Ltd24
Completed
Phase 2
TO Find the Effect of LION�S MANE CAPSULE as Nutritional SupplementHealth Condition 1: E089- Diabetes mellitus due to underlying condition without complicationsCTRI/2022/03/040725DXN Manufacturing India Pvt Ltd24
Active, not recruiting
Not Applicable
Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg plus Hydrochlorothiazide 25 mg in Patients with Severe HypertensioSubjects with severe essential hypertension (SBP between 150 mmHg and 200 mmHg AND DBP between 110 mmHg and 120 mmHg) who did not receive any antihypertensive treatment before will be included in the studyMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2009-011776-30-DETakeda Pharma GmbH100
Completed
Phase 2
TO Find the Effect of Codyceps Tablet as Nutritional SupplementHealth Condition 1: E089- Diabetes mellitus due to underlying condition without complicationsCTRI/2022/03/040784DXN Manufacturing India Pvt Ltd24